Purpose: Acinetobacter baumannii is an important opportunistic pathogen that causes pneumoniae, urinary tract infections, and/or septicemia in immunocompromised patients. This pathogen is frequently associated with nosocomial outbreaks worldwide and has become particularly problematic because of its prevalence and resistance patterns to several antibiotics. In the present study, we used an immunoproteome-based approach to identify immunogenic proteins located on the surface of A. baumannii for the development of a possible immunotherapy against this devastating bacterial infection. Experimental design: Sera from patients with A. baumannii infections (n = 50) and from a control group of healthy individuals (n = 3) were analyzed for reactivity against A. baumannii outer membrane proteins (OMPs) using Western blot analysis. To identify potential immunogenic proteins in A. baumannii, OMPs were separated by 2DE (2D electrophoresis), and reactive Q1 sera from infected patients were randomly selected and divided into two different pools, each containing 15 sera. Finally, MALDI-TOF/TOF mass spectrometric analysis was employed to identify the corresponding proteins. Results: This analysis identified six immunoreactive proteins: OmpA, Omp34kDa, OprC, OprB-like, OXA-23, and ferric siderophore receptor protein. Notably, these proteins are highly abundant on the bacterial surface and involved in virulence, antibiotic resistance, and growth. Conclusions and clinical relevance: Our results support the notion that the proteins identified in the present immunoproteome study could serve as antigen candidates for the development of vaccines and passive immunotherapies against A. baumannii infections.
Clinical Relevance
Acinetobacter baumannii has been associated with outbreaks of nosocomial infections in hospitals all over the world. The main infection caused by this microorganism is nosocomial pneumonia, but A. baumannii has also been associated with bacteremia, urinary tract infections, meningitis, and skin and soft tissue infections. The rapid emergence and global dissemination of A. baumannii as a major nosocomial pathogen is remarkable and demonstrates the successful adaptation of A. baumannii to the hospital environment. Mortality rates associated with A. baumannii infection have been reported to be between 35 and 70% for nosocomial pneumonias and between 20 and 60% for bacteremic infections. Infections caused by A. baumannii have increased dramatically and become more difficult to treat because of the emergence of highly antibiotic-resistant strains. These strains exhibit resistance to multiple antibiotic classes, and most problematic are recent descriptions of pan-resistant strains that are resistant to all antibiotics used in the clinic. There is particular concern regarding the development of carbapenem resistance, predominantly against imipenem and meropenem, the most important agents for the treatment of infections by MDR A. baumannii. For these reasons, it is necessary to identify new bacterial targets for the development of novel approaches to prevent and treat infections caused by this microorganism.
the 21st century hospital environment [2] . Mortality rates associated with A. baumannii infection have been reported to be between 35 and 70% for nosocomial pneumonias and between 20 and 60% for bacteremic infections [3] . Over the last three decades, the number of infections caused by A. baumannii has increased dramatically, and these infections have become more difficult to treat because of the emergence of highly antibiotic-resistant strains. These strains exhibit resistance to multiple antibiotic classes, and most problematic are recent descriptions of pan-resistant strains that are resistant to all clinically used antibiotics [4] . There is particular concern regarding the development of carbapenem resistance, mainly against imipenem and meropenem, which were introduced in 1985 and for years have been the most important agents for the treatment of infections by multidrug-resistant (MDR) A. baumannii [5] . For these reasons, it is necessary to identify new bacterial targets for the development of novel approaches to prevent and treat infections caused by this microorganism [4] .
Immunization could represent a potentially effective strategy for preventing infections caused by A. baumannii; however, to date, there have been no vaccines developed for this pathogen [3] . The development of immunotherapy for the treatment of bacterial infections typically focuses on targets such as virulence and colonization factors located on the bacterial membrane surface. Among these factors are the outer membrane proteins (OMPs) that may act as potential targets for adhesion with other cells and binding of bactericidal compounds on the Gram-negative bacteria surface [6] . Moreover, OMPs are involved in antibiotic resistance, nutrient transport, cell-cell signaling, host cell attachment, and virulence in pathogenic strains [1] . The characterization of OMPs is necessary because these proteins are highly abundant and in direct contact with the host immune system, making them good antigen candidates for the development of immunotherapy [7] .
The immunoproteomic approach enables the identification of pathogen antigens expressed during human infection and is a simple and efficient method to identify immunogenic proteins [7] . Proteomics, the large-scale study of proteins in a cell, tissue, or entire organism, allows for the fine description and overall characterization of protein expression [8] . Soares et al. [9] identified 37 OMPs from A. baumannii by 2DE analysis, but immunogenic proteins were not detected. In the present study, the 2D gel technique was used for the characterization of immunogenic proteins, followed by tandem mass spectrometric analysis and data mining for protein identification. The purpose was to identify antigens by immunoblotting with sera from A. baumannii infected patients. This approach led to the identification of several OMPs from A. baumannii that might be future targets for vaccine development.
Materials and methods

Bacterial strain and growth conditions
A MDR clinical strain of A. baumannii was grown overnight in Luria-Bertani broth (LB) with 50 g/mL ampicillin at 37ЊC under constant shaking. Overnight culture was diluted 1:100 v/v with fresh medium, and bacteria were grown to the exponential phase. Bacterial cells were pelleted by centrifugation at 10 000 × g for 10 min at 37ЊC. The supernatant was discarded, and the cell pellet was washed twice with 0.01 M PBS, pH 7.5. Washed cells were stored at −20ЊC. 
Membrane protein extraction of A. baumannii
The OMPs of A. baumannii were extracted by a modified previously described method [10] using 4% Triton R X-114. Briefly, bacterial culture was pelleted by centrifugation at 10 000 × g for 10 min at 37ЊC. The supernatant was discarded, and the cell pellet was washed twice with 0.01 M PBS, pH 7.5. Then, 1 g of the pellet was suspended in 10 mL of ice-cold TBS (50 mM Tris-HCl, 150 mM NaCl, pH 8.0) containing 4% Triton R X-114. The mixture was stirred overnight at 4ЊC and then centrifuged at 10 000 × g for 30 min at 4ЊC. The supernatant was incubated at 37ЊC for 3 h to separate the aqueous and detergent phases. The detergent phase containing the OMPs was collected. Proteins were precipitated with cold 100% acetone for 3 h at 4ЊC. The samples were centrifuged at 10 000 × g for 15 min at 37ЊC, the supernatant was discarded, and acetone was evaporated at 37ЊC. The protein concentration in the extracts was determined with a Bio-Rad protein assay kit by a modified Folin-Lowry assay, as suggested by Peterson [11] .
Human sera
Sera were collected from patients infected with Acinetobacter spp. (n = 50) in the period between October 2009 and December 2010 from five hospitals located in Rio de Janeiro, RJ. The identification of infected samples was performed using the automated method WalkAway Microscan (Dade Behring) or Vitek 2 (Biomerieux). All sera of patients infected with Acinetobacter spp. were analyzed individually by SDS-PAGE 12.5%, followed by immunoblotting. For immunoproteomic analysis, reactive sera were randomly selected and divided into two different pools, each containing 15 sera. A pool comprising three sera was obtained from healthy individuals and served as a negative control. The collected samples were properly recorded, and the data concerning the identity of patients were kept confidential. The current project was approved by the Ethics Committee in Research of the Evandro Chagas Research Institute (IPEC) at Fundação Oswaldo Cruz (Fiocruz; protocol number 0004.0.009.000-10).
1D gel electrophoresis and immunoblotting
The OMPs extracted from A. baumannii were analyzed by MiniProtean 3 (Bio-Rad) on 12.5% polyacrylamide gel in denaturing conditions according to Laemmli's method [12] . Sera from patients with A. baumannii infections (n = 50) and control group sera from healthy individuals (n = 3) were first individually analyzed for reactivity by Western blot against A. baumannii OMPs. Separated proteins were transferred from the 1DE gels to 0.45 mm nitrocellulose membranes
Q3
(Bio-Rad), as described by Towbin et al. [13] , for 90 min at 90 V. The membrane was incubated with each human serum overnight at a dilution of 1:200, followed by a secondary antibody [anti-human IgG HRP conjugate (Sigma-Aldrich R ) at a dilution of 1:15 000 v/v for 3 h. Proteins were detected using the color reagent Western Blue R Stabilized Substrate for Alkaline Phosphatase (Promega, USA).
2DE
The OMPs of A. baumannii were also analyzed by 2D electrophoresis. Extracts containing 60 g of proteins were solubilized in 7 M urea, 2 M thiourea, 4% w/v CHAPS, 1% v/v three to ten carrier ampholytes, 1% w/v bromophenol blue, and 60 mM DTT in a total volume of 125 L. For IEF, the IPGphor III system was used (GE Healthcare) with 7 cm strips, pH 3-10 (GE Healthcare). IEF was performed at 30 V for 12 h, followed by 200 V for 1 h, 500 V for 1 h, 1000 V for 1 h, a gradient to 3500 V for 30 min and 18 000 Vh, all at 20ЊC and 50 A. After IEF separation, strips were equilibrated for 2 × 15 min in equilibration buffer containing 50 mM Tris-Cl, pH 8.8, 6 M urea, 30% v/v glycerol, 2% w/v SDS, and 0.002% w/v bromophenol blue. DTT at 1% w/v was added to the first equilibration step, and 2.5% w/v iodoacetamide was added to the second. IPG strips were then placed over a 12.5% resolving polyacrylamide gel, and electrophoresis was performed at 2.5 mA/gel for 30 min, after which the current was increased to 20 mA/gel for 1 h. To prepare the 2DE gels for analysis, CBB G-250 (CBBG) colloidal staining was performed according to Candiano et al. [14] . Protein profiles were analyzed with Image Scanner II software (Amersham Biosciences), and the gels were stored in 1% acetic acid.
Immunoblotting
Separated proteins were transferred from the 2DE gels to 0.45 mm nitrocellulose membranes (Bio-Rad), as described by Towbin et al. [13] , for 90 min at 90 V. The membranes were blocked with 10% skim milk and 1% BSA in TBS (25 mM Tris-HCl pH 8.0; 0.15 mM NaCl) at room temperature for 2 h. Afterwards, the membranes were washed three times for 5 min. All washing steps were performed with TBS containing 0.05% Tween 20. Membranes were incubated overnight with two different pools, each containing 15 sera of patients infected with A. baumannii at a dilution of 1:200, followed by a secondary antibody [anti-human IgG HRP conjugate (SigmaAldrich R ) at a dilution of 1:15 000 v/v for 3 h. Before and after the addition of the secondary antibody, the membranes were washed four times for 15 min in TBS containing 0.05% Tween-20. Proteins were detected using the color reagent Western Blue R Stabilized Substrate for Alkaline Phosphatase (Promega, USA). The reactions were terminated by the addition of distilled water.
Protein digestion, peptide extraction, and MS
Proteins spots were excised and treated for in-gel digestion. Gel pieces were washed once with 100% ACN and dried in 1  2   3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57 Excess trypsin was removed, and the gels were incubated at 58ЊC for 30 min. The reactions were blocked with the addition of 1 L of 5% v/v formic acid. Peptides were extracted with 30 L of 5% v/v formic acid in 50% v/v ACN with sonication for 10 min. The extractions were performed twice to achieve a final volume of approximately 60 L. Samples containing the peptides were concentrated in a speed vac to approximately 10 L and finally desalted using a C 18 RP ZipTip (Millipore, Bedford, USA) microcolumn. The sample solutions (0.3 L) were mixed with an equal amount of a saturated matrix solution (CHCA (Aldrich, Milwaukee, WI) 10 mg/mL in 50% ACN/0.1% TFA) on the target plate and allowed to dry at room temperature (dried-droplet method). Raw data for protein identification were acquired on an AB Sciex 5800 (AB Sciex, Foster City, CA) MALDI mass spectrometer (see Supporting Information for raw data). Up to 12 of the most intense ion signals with S/N above 2 were selected as precursors for MS/MS acquisition, and common trypsin autolysis and keratine masses were excluded. External calibration in MS mode was performed using a mixture of five standard peptides: des 
Database search
The tandem mass spectra were searched against all entries of NCBInr (www.ncbi.nlm.nih.gov/index.html) using the Mascot software (www.matrixscience.com). The following search parameters were used: no restrictions on species of origin or protein molecular mass, tryptic cleavage products, two tryptic missed cleavages allowed, variable modifications of cysteine (carbamidomethylation), asparagine and glutamine (deamidation), methionine (oxidation), and pyroglutamate formation at the N-terminal glutamine of peptides.
Results and discussion
In the present study, OMPs of A. baumannii were extracted by a modified method using 4% Triton X-114 and resolved on a 1D gel. Individual sera of patients diagnosed with A. baumannii infection were used to identify OMPs that were recognized by the human immune system. Fifty sera of patients infected with A. baumannii were analyzed by immunoblotting with proteins resolved on 1D gels to determine the frequency of occurrence of the major immunogenic proteins in an individual serum. Examples could be seen in Fig. 1 and 1D immunoblottings of all 50 patients are represented in Supporting Information Fig. 1 . Healthy human sera were used Q4 as negative controls. We identified a protein with molecular weight in the range 38-40 kDa in 88% of the sera from infected patients with Acinetobacter spp., and other proteins at lower frequency were also detected (Table 1) . To better identify A. baumannii OMPs, reactive sera from infected patients were randomly selected and divided into two different pools, each containing 15 sera for immunoproteomic analyses. First, the OMPs of A. baumannii were resolved on a 2D CBBG colloidal stained gel to yield approximately 35 spots within the pI 3-10 range (Fig. 2) , indicating that the 2DE analysis provided a representative view of the A. baumannii proteome (Supporting Information Table 1) .
A total of 15 immunoreactive protein spots were observed from immunoblotting ( Fig. 3A and B) , and these spots matched with the protein spots observed in the preparative 2D gel (Fig. 2) . When the blot was probed with sera obtained from healthy individuals, no immunoreactive protein spots were observed. Protein identification was conducted using MALDI-MS/MS mass spectrometric analysis of the digested proteins followed by a search against the nonredundant National Center for Biotechnology Information (NCBI) database.
Despite the large amount of proteins present in the outer membrane fraction, few were immunogenic. Some reasons can be noted: (i) These proteins are generally embedded in the outer membrane, and therefore, only the outermost portion is in contact with the external environment. Thus, if only a few epitopes are present in the outermost region, it is normal to expect a lower immune response to these proteins in bacteria. In the 2DE, all proteins in the extracted membrane protein were represented, including proteins not exposed to the external environment. (ii) Some OMPs may be differentially expressed according to the environmental conditions [15] , particularly during the infectious process, which is different from in vitro culture, for example. (iii) In the 1D IB, we observed a low number of bands in Q5 the sera of some patients. This result may be because of the immune status of the patient, who is potentially immunocompromised [16] , therefore reflecting a lower response to the surface proteins of the bacterium.
(iv) The low number of the identified immunogenic proteins may be because of the limitations of the methodology used. However, immunoproteome analyses have been employed in previous studies to identify immunogenic proteins from the sera of infected patients [7, 16] . (v) Kurupati et al. [7] , employing immunoproteome analysis from Klebsiella pneumoniae, detected 60 proteins spots by 2DE and identified nine highly immunogenic proteins; only 15% of the spots were identified as immunogenic proteins. In our study, we detected 35 spots, and eight immunogenic proteins were identified; therefore, we conclude that our results are similar.
The immunogenic proteins identified in this work are summarized in Table 2 . Among the identified proteins, some have been previously characterized and are involved in pathogenesis, metal transport (iron, copper), and antibiotic resistance. 
OmpA
OMPs of Gram-negative bacteria are known to be key players in bacterial adaptation and pathogenesis in host cells [18] . OMP A (OmpA), identified in this study, has previously been well characterized in A. baumannii. This protein belongs to the OmpA superfamily of proteins, which are highly conserved across multiple species of Gram-negative bacteria, and OmpA of A. baumannii is also involved in many interactions with the host during infection, including adherence to epithelial cells, induction of apoptosis in host cells, and differentiation of host immune cells [4] . According to Soares [9] and co-workers, this protein is a precursor of Omp38, of the OmpA family, which is involved in the transport of ␤-lactams and saccharides with molecular masses of up to 800 Da. Furthermore, it has been suggested by the same authors that this protein can act as a potential virulence factor inducing apoptosis of epithelial cells in the early stages of infection by A. baumannii. For these reasons, OmpA might be an attractive target for the development of novel antibacterial therapies.
Omp34kDa
Omp34kDa, identified in this work, has been previously observed to be located on the outer membrane of A. baumannii. Importantly, this protein was recognized by antibodies of patients with an A. baumannii infection, but not by antibodies of patients without infection or infected by other pathogens. The protein has been demonstrated to be a specific antigenic protein in OMPs of A. baumannii, but further studies are required to decipher its role in the virulence or survival of the bacteria under adverse conditions [19] .
IROMP
When colonizing a host, bacterial pathogens, including A. baumannii, must compete with the host for essential nutrients. One of the most coveted nutrients in biological systems is iron because of its essentiality to almost all living organisms and limited availability under physiological conditions [20] . To survive in a human host, bacteria form siderophores called iron-regulated OMPs (IROMPs) [21] . In this study, we identified the ferric siderophore receptor protein. In host tissues, the availability of free Fe is minimal because most Fe is sequestered by high-affinity iron-binding proteins, such as transferrin and lactoferrin. Notably, OmpA is potentially involved in iron metabolism. Taken together, these findings open new avenues to explore and better understand the role of iron in the pathophysiology of A. baumannii [20] .
OprC
In the present study, OMPs associated with transport across the membrane of several compounds were also identified, including proteins such as outer membrane copper receptor (OprC), which allows the penetration of small cations and putative glucose-sensitive porin (OprB-like). This porin is often referred to as carbohydrate-selective porin because it acts as a central component of glucose, mannitol, glycerol, and fructose transport across the outer membrane [9] .
Porins can play a variety of roles depending on the bacterial species, including the maintenance of cellular structural integrity, bacterial conjugation and bacteriophage binding, antimicrobial resistance, and pore formation to permit the penetration of small molecules [22] [23] [24] [25] .
OXA-23
Acinetobacter baumannii is an important opportunistic Gramnegative pathogen frequently associated with nosocomial outbreaks worldwide. Carbapenems generally represent the last resort in treating life-threatening infections caused by Acinetobacter spp. because of their resistance against most ␤-lactamases, including extended-spectrum ␤-lactamases; however, their efficacy is increasingly compromised by the emergence of carbapenem-hydrolyzing ␤-lactamase enzymes of Ambler molecular class B (metallo-␤-lactamases) and D (oxacillinases) [26] . In this study, we identified OXA- 
Immunotherapy strategies
An important characteristic of a protein considered to be a good target for use in immunotherapy strategies is its degree of conservation in the same species (A. baumannii), in different species of Acinetobacter, and with other bacteria. This conservation ensures specific immune response against this pathogen, avoiding cross-reactivity with other microorganisms. Most of the proteins identified in this study are present in the genome of Acinetobacter deposited in Gene Bank and in another species of Acinetobacter, particularly A. calcoaceticus, A. lwoffii, A. nosocomialis, A. radioresistens, and A. johnsonii.
Infectious diseases are the second leading cause of death worldwide, and the acquisition of antibiotic resistance by many pathogenic bacteria has recently spurred interest in generating vaccines to cure or prevent diseases. OMPs are highly abundant proteins in direct contact with the host immune system, making them good targets for the development of immunotherapy for the treatment of bacterial infections [7] .
The feasibility of a vaccine against A. baumannii has been investigated in previous studies. McConnel et al. employed a killed whole-cell A. baumannii vaccine that protected immunized mice from infection [27] . These results confirm the effective potential of a vaccine against A. baumannii and are complementary to our study, which identified candidate antigens for the development of a recombinant protein-based vaccine.
In this work, the characterization of OMPs based on an immunoproteomic approach identified antigen candidates by immunoblotting with sera from A. baumannii infected patients. The presence of antibodies against a particular antigen in many patients is indicative of the expression of the respective protein in vivo and demonstrates that most individuals can mount an immune response against this protein; both of these results are requirements for a successful vaccine candidate [7] . It is particularly surprising that we identified an immunogenic protein related to antimicrobial resistance; however, previous reports have identified antibodies against chromosomal ␤-lactamase from Pseudomonas aeruginosa isolated from infected patients [28] .
Conclusions
The specific antigens OmpA, Omp34kDa, OprC, OprB-like, OXA-23, and ferric siderophore receptor protein of A. baumannii were major OMPs identified in this study as immunogenic proteins. Most of these antigens were conserved among A. baumannii and other Acinetobacter species.
These results suggest that these proteins could serve as antigen candidates for the development of immunotherapies against A. baumannii infections. Further studies must be performed with these immunogenic proteins to analyze their specific immunogenicities and protection abilities in animal models. 
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